These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9039624)

  • 1. Low molecular weight lanthanide contrast agents: in vitro studies of mechanisms of action.
    Fossheim S; Saebø KB; Fahlvik AK; Rongved P; Klaveness J
    J Magn Reson Imaging; 1997; 7(1):251-7. PubMed ID: 9039624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-molecular weight lanthanide contrast agents: evaluation of susceptibility and dipolar effects in red blood cell suspensions.
    Fossheim S; Kellar KE; Fahlvik AK; Klaveness J
    Magn Reson Imaging; 1997; 15(2):193-202. PubMed ID: 9106147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magnetic field dependence of solvent proton relaxation by solute dysprosium (III) complexes.
    Kellar KE; Fossheim SL; Koenig SH
    Invest Radiol; 1998 Nov; 33(11):835-40. PubMed ID: 9818318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NMRD investigation of DyDTPA- and GdDTPA-labeled starch particles. Selection of a suitable suspension medium and influence of the starch matrix on relaxivity.
    Fossheim SL; Spiller M; Kellar KE
    Invest Radiol; 1999 Apr; 34(4):287-95. PubMed ID: 10196721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lanthanide-based susceptibility contrast agents: assessment of the magnetic properties.
    Fossheim S; Johansson C; Fahlvik AK; Grace D; Klaveness J
    Magn Reson Med; 1996 Feb; 35(2):201-6. PubMed ID: 8622584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gadolinium-containing copolymeric chelates--a new potential MR contrast agent.
    Unger EC; Shen D; Wu G; Stewart L; Matsunaga TO; Trouard TP
    MAGMA; 1999 Aug; 8(3):154-62. PubMed ID: 10504042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MR imaging of contrast-enhanced porcine myocardial infarction. Assessment of reperfusion and tissue viability.
    Nilsson S
    Acta Radiol Suppl; 1995; 397():1-44. PubMed ID: 7484207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AUR Memorial Award. Identification of myocardial cell death in reperfused myocardial injury using dual mechanisms of contrast-enhanced magnetic resonance imaging.
    Geschwind JF; Wendland MF; Saeed M; Lauerma K; Derugin N; Higgins CB
    Acad Radiol; 1994 Dec; 1(4):319-25. PubMed ID: 9419506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysprosium-DOTA-PAMAM dendrimers as macromolecular T2 contrast agents. Preparation and relaxometry.
    Bulte JW; Wu C; Brechbiel MW; Brooks RA; Vymazal J; Holla M; Frank JA
    Invest Radiol; 1998 Nov; 33(11):841-5. PubMed ID: 9818319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Choice of metal ion and formulation concentration for first-pass brain perfusion studies with magnetic resonance imaging at 1.5 tesla.
    Runge VM; Wells JW
    Invest Radiol; 1996 Jul; 31(7):395-400. PubMed ID: 8818779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of gadolinium and dysprosium chelates as a cellular integrity marker in MR imaging.
    Ericsson A; Bach-Gansmo T; Niklasson F; Hemmingsson A
    Acta Radiol; 1995 Jan; 36(1):41-6. PubMed ID: 7833167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NMRD assessment of Gd-DTPA-bis(methoxyethylamide), (Gd-DTPA-BMEA), a nonionic MRI agent.
    Adzamli K; Periasamy MP; Spiller M; Koenig SH
    Invest Radiol; 1999 Jun; 34(6):410-4. PubMed ID: 10353033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of a binary chelate formulation: Could gadolinium based linear contrast agents be rescued by the addition of zinc selective chelates?
    Gibby W; Parish W; Merrill RM; Fernandez D; Anderson CR; Merchel E; Parr R
    Magn Reson Imaging; 2019 May; 58():76-81. PubMed ID: 30639754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ytterbium- and dysprosium-EOB-DTPA. A new prototype of liver-specific contrast agents for computed tomography.
    Krause W; Schuhmann-Giampieri G; Bauer M; Press WR; Muschick P
    Invest Radiol; 1996 Aug; 31(8):502-11. PubMed ID: 8854197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrovascular transit characteristics of DyDTPA-BMA and GdDTPA-BMA on normal and ischemic cat brain.
    Kucharczyk J; Asgari H; Mintorovitch J; Vexler Z; Rocklage S; Watson A; Moseley M
    AJNR Am J Neuroradiol; 1993; 14(2):289-96. PubMed ID: 8456701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action.
    Caravan P
    Acc Chem Res; 2009 Jul; 42(7):851-62. PubMed ID: 19222207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T1 relaxivities of gadolinium-based magnetic resonance contrast agents in human whole blood at 1.5, 3, and 7 T.
    Shen Y; Goerner FL; Snyder C; Morelli JN; Hao D; Hu D; Li X; Runge VM
    Invest Radiol; 2015 May; 50(5):330-8. PubMed ID: 25658049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging.
    Liang J; Sammet S; Yang X; Jia G; Takayama Y; Knopp MV
    Invest Radiol; 2010 May; 45(5):233-44. PubMed ID: 20351653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relaxivity of Gd-EOB-DTPA and Gd-DTPA in liver and kidney of the Wistar rat.
    Shuter B; Tofts PS; Wang SC; Pope JM
    Magn Reson Imaging; 1996; 14(3):243-53. PubMed ID: 8725190
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.